News MSD licenses Lp(a) heart drug from Hengrui in $2bn deal MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200m upfront.
News Novartis sheds staff as Entresto patent expiry looms Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.
News Liva buys Momenta to bolster digital health platform Liva Healthcare has acquired Momenta to create one of the largest providers of digital healthy lifestyle services to the NHS in England.
News Bayer files finerenone in EU for heart failure Bayer has filed its mineralocorticoid receptor antagonist finerenone as a treatment heart failure in the EU, but can it meet blockbuster sales hopes?
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl